NVAX

NVAX

USD

Novavax Inc. Common Stock

$7.510-0.175 (-2.277%)

Цена в режиме реального времени

Healthcare
Биотехнология
Соединенные Штаты

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$7.685

Максимум

$7.860

Минимум

$7.500

Объем

5.04M

Фундаментальные показатели компании

Рыночная капитализация

1.2B

Отрасль

Биотехнология

Страна

United States

Статистические данные торговли

Средний объем

6.00M

Биржа

NMS

Валюта

USD

52-недельный диапазон

Минимум $5.01Текущая $7.510Максимум $11.55

Связанные новости

Analyst Upgrades

TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7

TD Cowen analyst Brendan Smith maintains Novavax with a Hold and lowers the price target from $8 to $7.

Просмотреть больше
TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7
PR Newswire

Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™ to Sanofi, enabling...

Просмотреть больше
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Analyst Upgrades

Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Novavax with a Overweight rating and announces Price Target of $18.

Просмотреть больше
Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11

HC Wainwright & Co. analyst Sean Lee maintains Novavax with a Buy and raises the price target from $10 to $11.

Просмотреть больше
HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11
PR Newswire

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Novavax, Inc. (Nasdaq: NVAX) today announced that it has further executed against its planned transformation into a lean, agile operating model by...

Просмотреть больше
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.